Taking it to the U.S. Supreme Court

On Friday, The U.S. Supreme Court agreed to hear an appeal by Novartis AG on a 2015 federal appeals court decision that prevented the company from selling its biosimilar version of Amgen Inc.’s Neupogen until six months after the Food and Drug Administration approved it. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.